Innovent Biopharmaceutical Transformation
Enriching Our Pipeline with New Platform Technologies and New
Therapeutic Areas
Well Planned Portfolio Pipeline for Accelerated Growth
Solid foundation with de-risked, abundant
portfolio for early success
Well planned global portfolio for accelerated
growth equipped with world-class immunology
science, protein engineering, and collaboration
Approved
(2018-2022.1Q)
PD-1
About-to-launch
(2022-est.2023)
RET
Assets with Global or High
Market Potential
(2024 - 2026)
Oncology / Non-oncology (PoCed)
KRAS G12C
TIGIT, PD-1/TIGIT
VEGF/C3, VEGF/ANG-2,
VEGF-A/VEGF-C
GLP-1/GCGR
IL-23
LAG-3, PD-L1/LAG-3
BCMA CAR-T
VEGF
CD47, PD-L1/CD47,SIRPα
PD-1/IL-2, PD-1/IL-2/IL-21
PDE4
PCSK-9
CTLA-4
ROS1
80+ Research Programs
Global FIC/BIC
Blockbuster
(2026-)
ADC
ADC ISAC
T/NK engager
Immuno-cytokine
Pro-drug
Polymeric IgG
TNFα
CD20
FGFR1/2/3
BCR/ABL
VEGFR-2
Small Molecule
mAb
PI3K8*
CAR-T
Small Molecule
mAb
Multi-specific Ab
Multi-specific Ab
Cell therapy
CAR-T
Small Molecule
mAb
Powerful R&D Engine with Novel Science and Technologies
*Note: We plan to have communication with China NMPA regarding the potential submission of PI3KS. Incyte has withdrawn the application of
parsaclisib in FL, MZL and MCL in the U.S. as a business decision and is not related to any changes in either the efficacy or safety of parsaclisib.
innovent
Confidential
Copyright©2022 Innovent
Small molecule
mAb
15View entire presentation